Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1879 of 6351
-
RNA vaccine takes on malaria in first human trial
Vaccine CompletedThis first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP) encoding for part of the Plasmodium falciparum circum…
Phase 1 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Jun 26, 2026 13:12 UTC
-
Could buspirone and lofexidine take the edge off opioid withdrawal?
Symptom relief Recruiting nowThe investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise…
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC
-
Pre-Pregnancy diet may shield kids from obesity
Prevention OngoingThe study is a single site parallel randomized controlled study. The study will be assessing the effect of approximately 10% weight loss intervention vs a control group among healthy females/couples where the prospective mother is overweight or obese (BMI 27-45 kg/m\^2) and betw…
Sponsor: Christian Mølgaard • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Experimental combo targets tough blood cancers
Disease control Recruiting nowThe goal of this project is to see if two new potential treatments (defactinib and the combination tablet of decitabine/cedazuridine) can safely be combined to improve outcomes in people with high-risk myelodysplastic syndrome (MDS), certain forms of Acute Myeloid Leukaemia (AML)…
Phase 1 • Sponsor: Clinical Hub for Interventional Research (CHOIR) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New dialysis fluid aims to cut sugar side effects
Disease control Recruiting nowRandomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance) o…
Phase 3 • Sponsor: Iperboreal Pharma Srl • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cord blood shot may slow vision loss in dry AMD
Disease control Recruiting nowThe objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD)
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for swelling disorder: experimental drug enters human trials
Disease control OngoingThe first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).
Phase 1/2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug aims to control advanced cervical cancer
Disease control PausedTo learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Experimental cancer pill targets genetic weakness in Hard-to-Treat tumors
Disease control CompletedThis study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 help…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug aims to ease fatigue in mitochondrial disease
Symptom relief Recruiting nowThe primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms …
Phase 2 • Sponsor: Pharming Technologies B.V. • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
New scleroderma pill shows promise in slowing lung damage
Disease control CompletedThis study is open to adults aged 18 and older or above legal age who have systemic sclerosis. People can participate if they have a specific subtype called diffuse cutaneous systemic sclerosis. People with another subtype called limited cutaneous systemic sclerosis can also part…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New coil treatment aims to seal brain aneurysms
Disease control OngoingProspective, multi-center, non-randomized registry / study, up to 164 patients enrolled and followed at 180 days +/- 45 days and again at 365 days +/- 90 days post procedure
Sponsor: Kaneka Medical America LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody aims to stop bleeding episodes in rare clotting disorder
Disease control OngoingThe goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: * Parts A, B, and C: To determine the safety and tole…
Phase 1/2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug shows promise for dangerous fat levels in blood
Disease control OngoingThe purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Phase 3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Gene test may guide chemo choice for tough pancreatic cancer
Knowledge-focused Recruiting nowThe aim of this study is to assess the clinical value of 5 transcriptomic signatures prognostic of chemotherapeutic sensitivity to improve the Objective Response Rate (ORR) of first-line (L1). Chemotherapy regimen (FOLFIRINOX vs Gem-nabP) will be selected based on transcriptomic …
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
New light therapy could zap precancerous skin spots on Hard-to-Treat areas
Disease control CompletedThe aim of this study is to test the safety, tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment fo…
Phase 3 • Sponsor: Biofrontera Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Could a simple infusion let celiac patients eat gluten again?
Disease control CompletedThe goal of this clinical trial is to learn about the safety and the pharmacodynamic (PD) effects of TPM502 in adults with celiac disease. The main questions it aims to answer are: * if TPM502 is safe and well tolerated * if TPM502 can induce modifications in parameters indicati…
Phase 2 • Sponsor: Topas Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a home device help stroke survivors walk better?
Symptom relief Recruiting nowThis project will examine the feasibility, safety and effect of home-based functional electrical stimulation (FES) applied to different lower limb muscles in combination with task-specific training on gait, balance and mobility in adults with chronic stroke. 30 individuals with c…
Sponsor: University of Illinois at Chicago • Aim: Symptom relief
Last updated Jul 10, 2026 00:00 UTC
-
New pill shows promise for Long-Term relief of chronic hives
Disease control OngoingThe purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core stud…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Can a new drug slow friedreich ataxia? Long-Term trial underway
Disease control OngoingThe primary objective of this study is to assess the long-term safety of vatiquinone in participants with Friedreich ataxia (FA) previously exposed to vatiquinone.
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC